Stock screener

URGN

Conviction 86HealthcareScan · Thu, Sep 24, 2026
Hammer

UroGen Pharma Ltd. (URGN) closed at $41.22 (-0.98%) on Sep 24, 2026. Its latest daily candle is a hammer. Price is below its 50-day and above its 200-day moving average. RSI(14) 40, RS Rating 97, -18.0% from its 52-week high, +81.5% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

URGN$41.22-0.98%
ResistanceSupportVol 14Insider sell
63 bars
2
Vol MA14 829.61K
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
UroGen Pharma Ltd.PHARMACEUTICAL PREPARATIONSwww.urogen.com ↗
Price41.22
Change-0.98%
Gap-0.50%
Rel volume2.96×
Avg volume771.95K
Avg $ vol33.29M
SMA 2043.31
SMA 5043.91
SMA 20029.37
Price vs 50-6.14%
Price vs 200+40.33%
MA stackmixed
50/200 cross—
Supertrenddown · 46.79
RSI (14)40
MACD hist-0.28
MACD cross—
Stoch %K / %D20 / 25
ADX (14)14
+DI / −DI17 / 25
RSI divergence—
MACD divergenceBullish
ATR %4.98%
ADR %4.63%
52w high50.29
52w low16.42
From 52w high-18.04%
Above 52w low+151.04%
New 52w highNo
SqueezeOn · 5d
Bollinger width10.40%
%B0.04
Donchian pos20.44%
Donchian high47.06
Donchian low39.72
AVWAP (52w high)44.52
vs AVWAP high-7.42%
AVWAP (52w low)28.06
vs AVWAP low+46.90%
OBV trendDown
Chaikin MF (20)-0.02
Today vs 20d2.96×
Avg vol (14d)829.61K
Avg vol (20d)771.95K
Avg $ vol (20d)33.29M
Market cap2.01B
RS Rating97 / 99
RS 3m (vs SPY)+15.40%
RS 6m (vs SPY)+110.67%
RS line new highNo
Trend template7/8
Technical rank68.1
1 week-6.21%
1 month-11.09%
3 months+19.90%
6 months+127.48%
1 year+130.54%
YTD+81.51%
P/E-13.13
P/B-15.22
P/S18.35
P/FCF-12.38
EPS-4.96
Div yield—
ROE115.94%
ROA-60.77%
Debt/Eq-1.43
Current3.80
EV/EBITDA-17.06
Gross margin88.66%
Net margin-139.81%
Rev growth21.45%
EPS growth-20.98%
Price target60.20
Target upside46.05%
Analyst ratingBuy
Institutional87.72%
Ent. value2.12B
Revenue72.46M
Net income-14.35M
Gross profit65.88M
Free cash flow-162.73M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out48.72M
Employees291
ListedThu, May 4, 2017
Free float43.81M
Float %93.6%
Short interest6.25M
Days to cover6.8d
Short volume64.0%
Squeeze score85 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.28 vs −$0.38
Last surprise+26.3% beat
Setup gradeA+
Conviction86 / 100
Pattern quality—
Tech rank68.1 / 100
Group rank59 / 100
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmHammer

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in URGN

All disclosures →
No recent disclosed trades by Congress in URGN. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in URGN · open-market 4 sells

InsiderSideShares
Smith Jason Drew
General Counsel · Ordinary Shares · 2026-09-08
Sell1.52K
Schoenberg Mark
Chief Medical Officer · Ordinary Shares · 2026-09-08
Sell871
Smith Jason Drew
General Counsel · Ordinary Shares · 2026-09-07
Exercise3.33K
Smith Jason Drew
General Counsel · Restricted Stock Units · 2026-09-07
Exercise3.33K
Schoenberg Mark
Chief Medical Officer · Ordinary Shares · 2026-09-07
Exercise1.67K
Schoenberg Mark
Chief Medical Officer · Restricted Stock Units · 2026-09-07
Exercise1.67K
Robinson James A. Jr.
Director · ordinary shares · 2026-08-26
Exercise2K
Robinson James A. Jr.
Director · Restricted Stock Unit · 2026-08-26
Exercise2K
Schoenberg Mark
Chief Medical Officer · ordinary shares · 2026-08-20
Sell60.68K
Schoenberg Mark
Chief Medical Officer · Ordinary Shares · 2026-07-09
Sell10K

SEC filings

EDGAR filings in URGN · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.